Table 1.
Pooled demographics and baseline characteristics of patients treated with certolizumab pegol (CZP)
| All CZP (N = 995) | CZP 200 mg Q2W (N = 731) | CZP 400 mg Q2W (N = 728) | |
|---|---|---|---|
| Demographics | |||
| Age (years), mean ± SD | 45·6 ± 13·2 | 45·3 ± 13·1 | 45·7 ± 13·1 |
| Male, n (%) | 652 (65·5) | 491 (67·2) | 472 (64·8) |
| White, n (%) | 939 (94·4) | 694 (94·9) | 683 (93·8) |
| BMI (kg m−2), mean ± SD | 30·4 ± 7·0 | 30·2 ± 6·7 | 30·6 ± 7·1 |
| Weight (kg), mean ± SD | 90·7 ± 22·7 | 90·2 ± 21·4 | 91·4 ± 23·2 |
| Geographical region, n (%) | |||
| Central/Eastern Europe | 454 (45·6) | 336 (46·0) | 323 (44·4) |
| Western Europe | 181 (18·2) | 140 (19·2) | 151 (20·7) |
| North America | 360 (36·2) | 255 (34·9) | 254 (34·9) |
| Baseline disease characteristics | |||
| Psoriasis disease duration (years), mean ± SD | 18·2 ± 12·5 | 18·4 ± 12·6 | 18·2 ± 12·4 |
| Concomitant PsA, n (%) | 174 (17·5) | 127 (17·4) | 125 (17·2) |
| PASI, mean ± SD | 20·2 ± 7·8 | 20·1 ± 7·8 | 20·2 ± 7·7 |
| BSA (%), mean ± SD | 25·7 ± 15·3 | 25·5 ± 15·2 | 25·7 ± 15·0 |
| PGA score, n (%) | |||
| 3: moderate | 692 (69·5) | 509 (69·6) | 503 (69·1) |
| 4: severe | 303 (30·5) | 222 (30·4) | 225 (30·9) |
| Prior treatments, n (%) | |||
| Number of prior biologic therapies | |||
| 0 | 696 (69·9) | 510 (69·8) | 508 (69·8) |
| 1 | 228 (22·9) | 171 (23·4) | 166 (22·8) |
| 2 | 70 (7·0) | 50 (6·8) | 53 (7·3) |
| ≥ 3 | 1 (0·1) | 0 | 1 (0·1) |
| Anti‐TNF | 123 (12·4) | 94 (12·9) | 88 (12·1) |
| Anti‐IL‐17 | 149 (15·0) | 109 (14·9) | 106 (14·6) |
| Anti‐IL‐12/IL‐23 | 49 (4·9) | 30 (4·1) | 43 (5·9) |
| Prior chemotherapy or phototherapy | 475 (47·7) | 352 (48·2) | 360 (49·5) |
| Any prior systemic therapy for psoriasis | 714 (71·8) | 529 (72·4) | 532 (73·1) |
Patients who received both CZP 200 mg every 2 weeks (Q2W) and CZP 400 mg Q2W are included once in the population count for the ‘all CZP’ group. BMI, body mass index; BSA, body surface area; IL, interleukin; PASI, Psoriasis Area and Severity Index; PGA, Physician’s Global Assessment; PsA, psoriatic arthritis; SD, standard deviation; TNF, tumour necrosis factor.